Noul Co., Ltd. introduced its breakthrough Next Generation Immunoassay and Staining (NGSI) technology and their diagnostics platform, miLab™ at Korea’s largest biotech investment conference, Korea Bio Investment Conference (KBIC) on August 28th to 29th.

2019 Korea Bio Investment Conference (KBIC) was co-hosted by Korea Biotechnology Industry Organization and Korea Economic Daily to an audience of estimated 1,000 investors, fund managers, analysts, and VCs in biotech and pharmaceutical industries. 50 rising-star start-ups and corporations in the Korean bio and healthcare industries were selected to present at the exhibition to industry’s most influential guests and media attendees.

Noul’s co-founder and CEO David Lim introduced Noul’s breakthrough technology NGSI™ (Next Generation Staining and Immunoassay) and its main diagnostics platform, miLab™. The miLab™ diagnostic platform automates the workflow of a traditional manual microscopy test performed by a clinical laboratory – from sample slide-preparation to image review and diagnosis. miLab™ combines gold standard morphology-based diagnosis workflow into a fully automated and scalable point-of-care platform for small to medium-size laboratories and local clinics.

“We have updated the manual microscopy process that has been the gold standard for the past 100 years” said David Lim, CEO of Noul. “miLab™ empowers medical facilities with limited resources to conduct morphology-based confirmed diagnosis without large scale commitment for equipment, infrastructure, and skilled experts required in a traditional clinical laboratory setting.”

Noul is targeting a 1H 2020 release of the miLab™ diagnostics platform.